Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 2/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19092140 | 0.80 | CYP17A1 (0.33) | CCR1HTR6CDK4CDK6 | |
| SCHEMBL26026399 | 0.79 | SCN9A (0.33) | HTR6CDK4CDK6CDK2 | |
| SCHEMBL31745021 | 0.79 | CCR1 (0.38) | USP5CCR1TRPV4HTR6TSHR | |
| SCHEMBL20598022 | 0.79 | CCR1 (0.38) | USP5CCR1TRPV4HTR6TSHR | |
| SCHEMBL1135494 | 0.76 | CCR1 (0.79) | CCR1 | |
| SCHEMBL20598011 | 0.73 | GPR119 (0.45) | LMNAUSP2HSD17B10MEN1KMT2A | |
| SCHEMBL15916768 | 0.71 | EPHX2 (0.52) | USP5CCR1HTR6TSHRHSD11B1 | |
| SCHEMBL19092139 | 0.69 | KMT2A (0.62) | USP5TRPV4ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL4126308 | 0.69 | MAPT (0.50) | TSHRALDH1A1SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL568303 | 0.69 | CCR1 (0.70) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219689-A2 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-3397756-B1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CL) | 2019-10-03 | — | — | US | disclosed |
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CL) | 2019-10-03 | — | — | US | disclosed |
| US-20190000880-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2019-01-03 | — | — | US | disclosed |
| US-20190000880-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | KDM1B, KDM1A, KDM2A | USP5 608/4885CCR1 166/4885TRPV4 4228/4885 |
| US-20190000880-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | KDM1B, KDM1A, KDM2A | USP5 658/4885CCR1 179/4885TRPV4 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.